Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
25.21
-0.40 (-1.56%)
At close: Aug 31, 2026, 4:00 PM EDT
25.21
0.00 (0.00%)
Pre-market: Sep 1, 2026, 4:28 AM EDT

Ultragenyx Pharmaceutical Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
125421174213.58132.94307.58
Short-Term Investments
167259436363.63614.82432.61
Cash & Short-Term Investments
292680610577.21747.76740.2
Cash Growth
-40.11%11.47%5.68%-22.81%1.02%-38.40%
Accounts Receivable
20015812273.3940.4528.43
Other Receivables
2231.16.416
Receivables
20216012574.4946.8544.43
Inventory
59524533.9726.7716.23
Prepaid Expenses
44463044.51-55.75
Restricted Cash
91372.010.86-
Other Current Assets
----61.66-
Total Current Assets
606951817732.18883.9856.6
Property, Plant & Equipment
235267292314.47285.73176.18
Long-Term Investments
14457135199.9148.97293.86
Goodwill
44444444.4144.4144.41
Other Intangible Assets
172176178166.27160.11130.79
Other Long-Term Assets
63373733.7922.3420.56
Total Assets
1,2641,5321,5031,4911,5451,522

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
39313942.1143.2717.14
Accrued Expenses
221265241196.49204.68145.56
Current Portion of Long-Term Debt
76695029.24--
Current Portion of Leases
-121012.611.7811.07
Current Unearned Revenue
----1.487.61
Other Current Liabilities
1574---
Total Current Liabilities
351384344280.44261.21181.37
Long-Term Debt
1,1261,147820862.33875.44351.79
Long-Term Leases
-243030.5719.8130.9
Long-Term Unearned Revenue
-----1.47
Long-Term Deferred Tax Liabilities
30303030.0631.6733.31
Other Long-Term Liabilities
41201712.214.821.01
Total Liabilities
1,5481,6051,2411,2161,193599.84

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
---0.080.070.07
Additional Paid-In Capital
4,5184,4514,2133,6623,1402,997
Retained Earnings
-4,809-4,532-3,957-3,388-2,781-2,074
Treasury Stock
-10-8-4-0.43--
Comprehensive Income & Other
10931.08-6.57-1.4
Total Common Equity
-291-80255275.41352.49922.56
Minority Interest
777---
Shareholders' Equity
-284-73262275.41352.49922.56
Total Liabilities & Equity
1,2641,5321,5031,4911,5451,522

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
1,2021,252910934.74907.03393.76
Net Cash (Debt)
-766-515-165-157.63-10.3605.37
Net Cash Growth
------26.90%
Net Cash Per Share
-7.62-5.22-1.82-2.14-0.158.93
Filing Date Shares Outstanding
98.2996.4392.582.3470.2269.38
Total Common Shares Outstanding
98.396.492.4882.3270.269.34
Working Capital
255567473451.75622.69675.24
Book Value Per Share
-2.96-0.832.763.355.0213.30
Tangible Book Value
-507-3003364.74147.98747.37
Tangible Book Value Per Share
-5.16-3.110.360.792.1110.78
Land
-171716.6216.6215.49
Buildings
-182182181.362.8-
Machinery
-125119116.2670.2854.31
Construction In Progress
----189.4576.85
Leasehold Improvements
-555858.6843.9444.08
SEC Filings: 10-K · 10-Q